C5 and atypical hemolytic-uremic syndrome: Eculizumab is a monoclonal antibody that blocks C5 cleavage, thereby preventing the formation of the pro-inflammatory peptides C5a and C5b-9 membrane attack complex, which are central to the pathophysiology of aHUS (20).